Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Statins May Improve Outcomes and Toxicities in Patients Undergoing CD19-Specific CAR T-Cell Therapy for Aggressive B-Cell Lymphomas

Shubham Adroja, Ethan A Burns, Noah Giese, Sunil Mathur, Meera Khosla, Jacqueline Rios, Hala S Hassanain, Premal D. Lulla, Carlos A. Ramos, Carrie Yuen, Chih-Hang Anthony Tang, Chih-Chi Andrew Hu, Siddhartha Ganguly, Helen Elisabeth Heslop, Sai Ravi Kiran Pingali

Blood (2024) 144 (Supplement 1): 5131.

https://doi.org/10.1182/blood-2024-211656

Published: 2024

Journal Articles

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

Blood (2024) 143 (13): 1231–1241.

https://doi.org/10.1182/blood.2023022204

Published: 2024

Includes: Supplemental data

Journal Articles

Immune Profiling of Respiratory Syncytial Virus (RSV) for the Development of Targeted Immunotherapy

Penelope Papayanni, Kiriakos Koukoulias, Manik Kuvalekar, Ayumi Watanabe, Yovana Velazquez, Carlos A. Ramos, Ann M. Leen, Spyridoula Vasileiou

Blood (2023) 142 (Supplement 1): 6818.

https://doi.org/10.1182/blood-2023-172491

Published: 2023

Journal Articles

CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma

Blood (2022) 140 (Supplement 1): 412–414.

https://doi.org/10.1182/blood-2022-160244

Published: 2022

Journal Articles

Phase 1b/2 Study of Autologous CD30.CAR-T Cells in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma after Failure of Frontline Therapy (ACTION)

Matthew Mei, Sairah Ahmed, Amer Beitinjaneh, Natalie S. Grover, Carlos A. Ramos, Khong Bee Kang, Paul I. Nadler, Aung Myo, Ivan D. Horak, Helen E. Heslop

Blood (2022) 140 (Supplement 1): 12728–12730.

https://doi.org/10.1182/blood-2022-157131

Published: 2022

Journal Articles

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Blood (2022) 140 (1): 16–24.

https://doi.org/10.1182/blood.2022015728

Published: 2022

Journal Articles

Allogeneic NKT Cells Expressing a CD19-Specific CAR in Patients with Relapsed or Refractory B-Cell Malignancies: An Interim Analysis

Carlos A. Ramos, Amy N. Courtney, Simon N. Robinson, Olga Dakhova, Premal D. Lulla, Rammurti Kamble, George Carrum, Tao Wang, Chunchao Zhang, Erica Di Pierro, Leonid S. Metelitsa

Blood (2021) 138 (Supplement 1): 2819.

https://doi.org/10.1182/blood-2021-149712

Published: 2021

Journal Articles

Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

Blood (2021) 138 (Supplement 1): 1763.

https://doi.org/10.1182/blood-2021-153421

Published: 2021

Journal Articles

Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant

Blood (2021) 137 (19): 2585–2597.

https://doi.org/10.1182/blood.2020009471

Published: 2021

Includes: Supplemental data

Journal Articles

Level of Evidence for FDA Drug Approvals in Pivotal Clinical Trials of Hematological Malignancies

Samer Al Hadidi, MDMSc,FACP, Carlos A. Ramos, MD

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-136330

Published: 2020

Journal Articles

A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

David H. Quach, PhD, Haran R. Ganesh, BS, Sachin Thakkar, PhD, Luis Becerra-Dominguez, BS, Birju Mehta, MS, Silvana Perconti, MS, Eric Anderson, BS, Emily M. Hsieh, MD, Olga Dakhova, MD, Huimin Zhang, BS, Bambi J. Grilley, RPh, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MD DSc, Carlos A. Ramos, MD, Rayne H. Rouce, MD, Natalia Lapteva, PhD, Cliona M. Rooney, PhD

Blood (2020) 136 (Supplement 1): 16.

https://doi.org/10.1182/blood-2020-141491

Published: 2020

Journal Articles

Treatment of Severe, Drug-Refractory Viral Infections with Allogeneic, Off-the-Shelf Multi-Virus Specific T Cells in Patients Following HSCT: Results from a Phase 2 Study

Ifigeneia Tzannou, MD, Ayumi Watanabe, Bsc, Anastasia Papadopoulou, PhD, Manik Kuvalekar, Msc, Swati Naik, MBBS, Premal Lulla, MBBS, Robert A. Krance, MD, Carlos A. Ramos, MD, Helen E. Heslop, MD DSc, Ann M. Leen, PhD, Bilal Omer, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-143037

Published: 2020

Journal Articles

T Cell Immunity Toward Viral- and Tumor-Antigens Is Preserved in MDS Patients

Hussein Hamad, MD, Wingchi K Leung, MD, Spyridoula Vasileiou, PhD, Shivani Mukhi, Quillan Huang, MD, George Carrum, MD, Carlos A. Ramos, MD, Rammurti Kamble, MD, LaQuisa C. Hill, MD, Ann M. Leen, PhD, Premal Lulla, MBBS

Blood (2019) 134 (Supplement_1): 4225.

https://doi.org/10.1182/blood-2019-126792

Published: 2019

Journal Articles

Novel Immunotherapeutic Approaches for Hodgkin Lymphoma

Barbara Savoldo, MD PhD, Natalie S Grover, MD, Carlos A. Ramos, MD, Gianpietro Dotti, MD

Blood (2019) 134 (Supplement_1): SCI-9.

https://doi.org/10.1182/blood-2019-121075

Published: 2019

Journal Articles

Adoptive T-Cell Therapy for Acute Lymphoblastic Leukemia Targeting Multiple Tumor Associated Antigens

Swati Naik, MBBS, Premal Lulla, MBBS, Ifigeneia Tzannou, MD, Robert A. Krance, MD, George Carrum, MD, Rammurti Kamble, MD, Carlos A. Ramos, MD, Catherine Robertson, Manik Kuvalekar, Ayumi Watanabe, Bambi J. Grilley, RPh, Juan F. Vera, MD, Helen E. Heslop, MDDSc, Ann M. Leen, PhD

Blood (2018) 132 (Supplement 1): 2693.

https://doi.org/10.1182/blood-2018-99-115465

Published: 2018

Journal Articles

Rapid Generation of Multivirus-Specific T Lymphocytes for the Prevention and Treatment of Respiratory Viral Infections

Spyridoula Vasileiou, PhD, Annie Turney, Manik Kuvalekar, Shivani Mukhi, Ayumi Watanabe, Premal Lulla, MBBS, Carlos A. Ramos, MD, Juan Vera, MD, Ifigeneia Tzannou, MD, Ann Leen, PhD

Blood (2018) 132 (Supplement 1): 3332.

https://doi.org/10.1182/blood-2018-99-113168

Published: 2018

Journal Articles

Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma

Premal Lulla, MBBS, Ifigeneia Tzannou, MD, George Carrum, MD, Carlos A. Ramos, MD, Rammurti Kamble, MD, Mrinalini Bilgi, Shivani Mukhi, Betty Chung, DO,MPH,MA, Ayumi Watanabe, Manik Kuvalekar, Adrian P. Gee, PhD, Bambi J. Grilley, RPh, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MDDSc, Juan F. Vera, MD, Ann M. Leen, PhD

Blood (2018) 132 (Supplement 1): 1014.

https://doi.org/10.1182/blood-2018-99-113118

Published: 2018

Journal Articles

CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL)

Carlos A. Ramos, MD, Mrinalini Bilgi, Claudia P. Gerken, Olga Dakhova, Zhuyong Mei, Bambi J. Grilley, RPh, Adrian P. Gee, PhD, Cliona M. Rooney, PhD, Gianpietro Dotti, MD, Barbara Savoldo, MD PhD, Helen E. Heslop, MDDSc, Malcolm K. Brenner, MD PhD

Blood (2018) 132 (Supplement 1): 680.

https://doi.org/10.1182/blood-2018-99-111202

Published: 2018

Journal Articles

Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells

George Carrum, MD, Premal Lulla, MBBS, Ifigeneia Tzannou, MD, Ayumi Watanabe, Manik Kuvalekar, Mrinalini Bilgi, Rammurti Kamble, MD, Carlos A. Ramos, MD, Rayne Rouce, MD, Bambi J. Grilley, RPh, Adrian P. Gee, PhD, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MDDSc, Cliona M. Rooney, PhD, Juan F. Vera, MD, Ann M. Leen, PhD

Blood (2018) 132 (Supplement 1): 1685.

https://doi.org/10.1182/blood-2018-99-113140

Published: 2018

Journal Articles

Adoptive Immunotherapy with Rapidly-Generated Multivirus-Specific T Cells Against AdV, EBV, CMV, HHV6 and BK after Allogeneic Hematopoietic Stem Cell Transplant

Blood (2017) 130 (Supplement 1): 4484.

https://doi.org/10.1182/blood.V130.Suppl_1.4484.4484

Published: 2017

NARROW

Statins May Improve Outcomes and Toxicities in Patients Undergoing CD19-Specific CAR T-Cell Therapy for Aggressive B-Cell Lymphomas

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

Immune Profiling of Respiratory Syncytial Virus (RSV) for the Development of Targeted Immunotherapy

CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma

Phase 1b/2 Study of Autologous CD30.CAR-T Cells in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma after Failure of Frontline Therapy (ACTION)

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Allogeneic NKT Cells Expressing a CD19-Specific CAR in Patients with Relapsed or Refractory B-Cell Malignancies: An Interim Analysis

Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant

Level of Evidence for FDA Drug Approvals in Pivotal Clinical Trials of Hematological Malignancies

A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

Treatment of Severe, Drug-Refractory Viral Infections with Allogeneic, Off-the-Shelf Multi-Virus Specific T Cells in Patients Following HSCT: Results from a Phase 2 Study

T Cell Immunity Toward Viral- and Tumor-Antigens Is Preserved in MDS Patients

Novel Immunotherapeutic Approaches for Hodgkin Lymphoma

Adoptive T-Cell Therapy for Acute Lymphoblastic Leukemia Targeting Multiple Tumor Associated Antigens

Rapid Generation of Multivirus-Specific T Lymphocytes for the Prevention and Treatment of Respiratory Viral Infections

Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma

CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL)

Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells

Adoptive Immunotherapy with Rapidly-Generated Multivirus-Specific T Cells Against AdV, EBV, CMV, HHV6 and BK after Allogeneic Hematopoietic Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only